Scientists researching drugs that could improve brain function in people with schizophrenia

October 12, 2017 by Leah Small, Virginia Commonwealth University
Scientists researching drugs that could improve brain function in people with schizophrenia
Credit: Virginia Commonwealth University

Virginia Commonwealth University researchers are testing if drugs known as HDAC inhibitors improve cognition in patients with schizophrenia who have been treated with the antipsychotic drug clozapine.

Clozapine, which has been shown to be the most effective available antipsychotic for hallucinations and delusion treatment, may impair memory and attention, said Ananda Pandurangi, M.D., medical director and chair of inpatient psychiatry in the Department of Psychiatry at VCU School of Medicine. Pandurangi is an investigator on the clinical trial.

"By improving symptoms associated with schizophrenia such as hallucinations and behavior disorder, indirectly improves cognition," Pandurangi said. For example, he said, a person who is not hallucinating can better concentrate and interact with others, which provides social stimulation that enhances cognition. However, Pandurangi added, clozapine may diminish individual cognitive functions such as short-term memory.

Researchers hypothesize that HDAC inhibitors, which repress the functions of a specific family of proteins, could prevent an adverse mechanism that results from clozapine's interaction with the brain.

"Clozapine's potential to further benefit memory, attention and other aspects of cognition may be constrained by one of its own actions, which HDAC inhibitors could prevent," Pandurangi said.

Clozapine and the brain

Javier González-Maeso, Ph.D., associate professor of physiology and biophysics at VCU School of Medicine, discovered the mechanism that HDAC inhibitors would target. He first noticed an increase in the protein HDAC2 that may result from chronic treatment of schizophrenia with clozapine. He then found that inhibiting the function of HDAC2 in associated neurons may improve cognition.

HDAC2 is one of a group of proteins that makes potentially inheritable changes to the way a gene impacts observable characteristics of an individual, such as behavior.

González-Maeso and Pandurangi are currently recruiting people with schizophrenia for a pilot study to test the effectiveness of the drug vorinostat, which is currently used to treat skin cancer, as an HDAC2 inhibitor. The study will be the start of determining if HDAC2 could be a new target for schizophrenia treatment.

"In post-mortem samples of patients, we found the same pathway that was affected by clozapine in mice was in the frontal cortex of people with schizophrenia who had been treated with antipsychotics," González-Maeso said.

González-Maeso's work was published in the journal Nature Neuroscience in August and is funded by the National Institute of Mental Health. Researchers at the Icahn School of Medicine at Mount Sinai in New York and the University of the Basque Country in Bilbao, Spain, contributed to initial experiments on mice and post-mortem human samples.

Members of González-Maeso lab group, who worked extensively on the published findings, from left to right: Maryum Ijaz, Javier González-Maeso, Ph.D.; Justin Saunders, Mario de la Fuente Revenga, Ph.D. Credit: Tom Kojcsich, University Marketing

González-Maeso began testing vorinostat for its impact on cognition due to the drug's known ability to inhibit proteins that belong to the HDAC family. It is possible that more specific HDAC inhibitors could be tested because much is still unknown about vorinostat's effectiveness for the newly identified potential use.

If the researchers are able to further prove the concept through human trials, people with schizophrenia could avoid psychosis while improving cognitive function.

"Schizophrenia is a devastating disease," González-Maeso said. "The cognitive dysfunction in is one of the core impairments that negatively affect quality of life for these patients. Life would be so much better for our patients with a drug that treated dysfunction."

Finding the key

A discovery by González-Maeso published in Nature Neuroscience in 2012 laid the groundwork for the investigation of vorinostat's capabilities. The scientist found when HDAC2 increases in the brain after chronic clozapine treatment, it impairs glutamate, which is involved in cognition and other functions and is the most abundant neurotransmitter in the body. HDAC2 also reduces the functionality of the mGlu2 glutamate receptor, which has a role in memory.

"What we have is a lock-and-key mechanism," Pandurangi said. "To open the door you need a particular key. The lock is the mGlu2 receptor and the key is glutamate. HDAC2 inhibitors will make the key work better with the lock."

Testing phases

González-Maeso recently completed experiments on blocking the function of HDAC2 in mice and tested the impact of clozapine on the recognition memory of mice. These findings inform hypotheses for how HDAC2 and clozapine impact the human brain. To measure recognition memory, he set up two testing groups. One was treated chronically with clozapine and the other was a control group that was not medicated. The mice were exposed to two objects on a single day. On the following day, one of those objects was changed.

"Normal mice show curiosity for the new object and spend time exploring it," González-Maeso said.

Mice treated chronically with clozapine do not, he said.

"They cannot remember the initial object from the previous day, so they don't recognize the change," González-Maeso said.

Following completion of the first human trial, González-Maeso and Pandurangi plan to conduct large trials in collaboration with multiple institutions to continue testing the efficacy of HDAC2 inhibitors.

Explore further: Researchers identify new drug target for schizophrenia

More information: Daisuke Ibi et al. Antipsychotic-induced Hdac2 transcription via NF-κB leads to synaptic and cognitive side effects, Nature Neuroscience (2017). DOI: 10.1038/nn.4616

Related Stories

Researchers identify new drug target for schizophrenia

August 13, 2012
(Medical Xpress) -- Researchers at Mount Sinai School of Medicine may have discovered why certain drugs to treat schizophrenia are ineffective in some patients. Published online in Nature Neuroscience, the research will pave ...

New research suggests alternative treatment target for schizophrenia

February 3, 2016
A new study by Virginia Commonwealth University researchers suggests that dysregulation in the way two G protein-coupled receptors talk to each other may be responsible for some symptoms of schizophrenia and could lead to ...

Blocking enzyme linked to Alzheimer's may reverse memory loss

August 8, 2017
In the brains of Alzheimer's patients, many of the genes required to form new memories are shut down by a genetic blockade, contributing to the cognitive decline seen in those patients.

Clozapine benefits those with tx-resistant schizophrenia

December 1, 2015
(HealthDay)—Clozapine reduces symptoms in patients with schizophrenia who don't benefit from other antipsychotic medications, according to research published online Nov. 6 in The American Journal of Psychiatry.

Better options for people with treatment-resistant schizophrenia

November 6, 2015
In real-world settings, patients with schizophrenia whose symptoms do not respond to standard antipsychotic medications have better outcomes if they are switched to clozapine instead of another standard antipsychotic. They ...

Antipsychotic drug clozapine found to have significant gastrointestinal side effects

February 24, 2016
New research from the University of Otago, Wellington, and Capital and Coast Health District Health Board (CCDHB) shows that the antipsychotic drug clozapine dramatically slows bowel function. Rarely, this can lead to serious ...

Recommended for you

Researchers replicate famous marshmallow test, makes new observations

May 25, 2018
A new replication study of the well-known "marshmallow test—a famous psychological experiment designed to measure children's self-control—suggests that being able to delay gratification at a young age may not be as predictive ...

Can we really tell if it's love at first sight?

May 25, 2018
Long-term and short-term relationships are obviously different from each other. Some people are the type you'd want to marry; others are good primarily for the sex.

People with family history of alcoholism release more dopamine in expectation of alcohol

May 23, 2018
People with a family history of alcohol use disorder (AUD) release more dopamine in the brain's main reward center in response to the expectation of alcohol than people diagnosed with the disorder, or healthy people without ...

Why we fail to understand our smartphone use

May 23, 2018
Checking your phone dozens of times a day indicates unconscious behaviour, which is "extremely repetitive" say psychologists.

Study confirms that men and women tend to adopt different navigation strategies

May 23, 2018
When navigating in a known environment, men prefer to take shortcuts to reach their destination more quickly, while women tend to use routes they know. This is according to Alexander Boone of UC Santa Barbara in the US who ...

Early life trauma in men associated with reduced levels of sperm microRNAs

May 22, 2018
Exposure to early life trauma can lead to poor physical and mental health in some individuals, which can be passed on to their children. Studies in mice show that at least some of the effects of stress can be transmitted ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.